Skip to main content
Top
Published in: Investigational New Drugs 3/2011

01-06-2011 | PRECLINICAL STUDIES

Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan

Authors: Sergio Cafaggi, Eleonora Russo, Rossana Stefani, Brunella Parodi, Gabriele Caviglioli, Greta Sillo, Angela Bisio, Cinzia Aiello, Maurizio Viale

Published in: Investigational New Drugs | Issue 3/2011

Login to get access

Summary

In this work, nanoparticles with a positive surface charge were prepared through the electrostatic interaction of a new cisplatin-hyaluronate complex with N-trimethyl chitosan (substitution degree of 85%). Mean particle diameter was approximately 195 nm. Drug loading of nanoparticles, which had a zeta potential of about 27 mV, was equal to 6% w/w. After 24 h, while the cisplatin-hyaluronate complex released approximately 60% w/w drug in phosphate buffered saline at pH 7.4, approximately 40% w/w of total cisplatin was released from nanoparticles. The same cumulative amounts of released drug were found after 48 h. These nanoparticles, as well as the starting cisplatin-hyaluronate complex, were active on all cell lines tested (P388, A2780, A549), with an antiproliferative activity similar to that of cisplatin. Apoptosis was markedly induced in A2780 cells by nanoparticles. In a preliminary in vivo experiment, the antitumour activity against a murine tumour (P388 cells) subcutaneously implanted in mice, resulted similar to that of cisplatin for nanoparticles whereas the starting complex showed a non-significant activity at the cisplatin dose tested. Body weight change of treated mice suggested a significantly better tolerance of the nanoparticles compared to cisplatin, after an initial brief period of acute toxicity higher than the parent drug. These results indicate that such a particulate system could be useful as a carrier for cisplatin delivery.
Literature
1.
go back to reference Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M (1989) Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res 9:1121–1128PubMed Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M (1989) Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res 9:1121–1128PubMed
2.
go back to reference Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R (1999) Hpma copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 35:994–1002PubMedCrossRef Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G, Duncan R (1999) Hpma copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 35:994–1002PubMedCrossRef
3.
go back to reference Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10:767–776PubMedCrossRef Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10:767–776PubMedCrossRef
4.
go back to reference Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, Xi X, Wu Z (2006) Poly-(γ, l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27:5958–5965PubMedCrossRef Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, Xi X, Wu Z (2006) Poly-(γ, l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27:5958–5965PubMedCrossRef
5.
go back to reference Schlechter B, Neumann A, Wilchek M, Arnon R (1989) Soluble polymers as carriers of cis-platinum. J Controll Release 10:75–87CrossRef Schlechter B, Neumann A, Wilchek M, Arnon R (1989) Soluble polymers as carriers of cis-platinum. J Controll Release 10:75–87CrossRef
6.
go back to reference Imai T, Fujii K, Shiraishi S, Otagiri M (1997) Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. J Pharm Sci 86:244–247PubMedCrossRef Imai T, Fujii K, Shiraishi S, Otagiri M (1997) Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. J Pharm Sci 86:244–247PubMedCrossRef
7.
go back to reference Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G, De Totero D, Aiello C, Viale M (2007) Preparation and evaluation of nanoparticles made of chitosan or n-trimethyl chitosan and a cisplatin-alginate complex. J Controll Release 121:110–123CrossRef Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G, De Totero D, Aiello C, Viale M (2007) Preparation and evaluation of nanoparticles made of chitosan or n-trimethyl chitosan and a cisplatin-alginate complex. J Controll Release 121:110–123CrossRef
8.
go back to reference Avichezer D, Schechter B, Arnon R (1998) Functional polymers in drug delivery: carrier-supported cddp (cis-platin) complexes of polycarboxylates—effect on human ovarian carcinoma. Reactive Funct Polymers 36:59–69CrossRef Avichezer D, Schechter B, Arnon R (1998) Functional polymers in drug delivery: carrier-supported cddp (cis-platin) complexes of polycarboxylates—effect on human ovarian carcinoma. Reactive Funct Polymers 36:59–69CrossRef
9.
go back to reference Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M (2006) Tumor cells enhance their own cd44 cleavage and motility by generating hyaluronan fragments. J Biol Chem 281:5861–5868PubMedCrossRef Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M (2006) Tumor cells enhance their own cd44 cleavage and motility by generating hyaluronan fragments. J Biol Chem 281:5861–5868PubMedCrossRef
10.
go back to reference Yip GW, Smollich M, Gotte M (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Therap 5:2139–2148CrossRef Yip GW, Smollich M, Gotte M (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Therap 5:2139–2148CrossRef
11.
go back to reference Ravi Kumar MNV (2001) A review of chitin and chitosan applications. Reactive Funct Polymers 46:1–27CrossRef Ravi Kumar MNV (2001) A review of chitin and chitosan applications. Reactive Funct Polymers 46:1–27CrossRef
12.
go back to reference Calvo P, Remunan-Lopez C, Vila-jato JL, Alonso MJ (1997) Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125–132CrossRef Calvo P, Remunan-Lopez C, Vila-jato JL, Alonso MJ (1997) Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125–132CrossRef
13.
go back to reference Mi FL, Sung HW, Shyu SS (2001) Release of indomethacin from a novel chitosan microsphere prepared by naturally occurring crosslinker: examination of crosslinking and polycation/anionic drug interaction. J Appl Polym Sci 81:1700–1711CrossRef Mi FL, Sung HW, Shyu SS (2001) Release of indomethacin from a novel chitosan microsphere prepared by naturally occurring crosslinker: examination of crosslinking and polycation/anionic drug interaction. J Appl Polym Sci 81:1700–1711CrossRef
14.
go back to reference Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W (2006) Preparation and characterization of protein-loaded n-trimethyl chitosan nanoparticles as nasal delivery system. J Controll Release 111:107–116CrossRef Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W (2006) Preparation and characterization of protein-loaded n-trimethyl chitosan nanoparticles as nasal delivery system. J Controll Release 111:107–116CrossRef
15.
go back to reference Hamman JH, Stander M, Kotzé AF (2002) Effect of the degree of quaternization of n-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm 232:235–242PubMedCrossRef Hamman JH, Stander M, Kotzé AF (2002) Effect of the degree of quaternization of n-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm 232:235–242PubMedCrossRef
16.
go back to reference Lee J-K, Lim H-S, Kim J-H (2002) Cytotoxic activity of aminoderivatized cationic chitosan derivatives. Bioorg Med Chem Lett 12:2949–2951PubMedCrossRef Lee J-K, Lim H-S, Kim J-H (2002) Cytotoxic activity of aminoderivatized cationic chitosan derivatives. Bioorg Med Chem Lett 12:2949–2951PubMedCrossRef
17.
go back to reference Kean T, Roth S, Thanou M (2005) Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J Controll Release 103:643–653CrossRef Kean T, Roth S, Thanou M (2005) Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J Controll Release 103:643–653CrossRef
18.
go back to reference Haas J, Kumar MNVR, Borchard G, Bakowsky U, Lehr C-M (2005) Preparation and characterization of chitosan and trimethyl-chitosan modified poly-(ε-caprolactone) nanoparticles as DNA carriers. AAPS PharmSciTech 6:E22–E30PubMedCrossRef Haas J, Kumar MNVR, Borchard G, Bakowsky U, Lehr C-M (2005) Preparation and characterization of chitosan and trimethyl-chitosan modified poly-(ε-caprolactone) nanoparticles as DNA carriers. AAPS PharmSciTech 6:E22–E30PubMedCrossRef
19.
go back to reference Russo E, Stefani R, Parodi B, Caviglioli G, Aiello C, Viale M, Cafaggi S, Bignardi G (2008) Cisplatin delivery: a study on a cisplatin-hyaluronate complex and nanoparticles formed by its interaction with n-trimethyl chitosan. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Barcelona Russo E, Stefani R, Parodi B, Caviglioli G, Aiello C, Viale M, Cafaggi S, Bignardi G (2008) Cisplatin delivery: a study on a cisplatin-hyaluronate complex and nanoparticles formed by its interaction with n-trimethyl chitosan. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Barcelona
20.
go back to reference Jeong Y-I, Kim S-T, Jin S-G, Ryu H-H, Jin Y-H, Jung T-Y, Kim I-Y, Jung S (2008) Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 97:1268–1276PubMedCrossRef Jeong Y-I, Kim S-T, Jin S-G, Ryu H-H, Jin Y-H, Jung T-Y, Kim I-Y, Jung S (2008) Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 97:1268–1276PubMedCrossRef
21.
go back to reference Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML (2008) Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 147:247–252PubMedCrossRef Cai S, Xie Y, Bagby TR, Cohen MS, Forrest ML (2008) Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 147:247–252PubMedCrossRef
22.
go back to reference Peer D, Margalit R (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6:343–353PubMedCrossRef Peer D, Margalit R (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6:343–353PubMedCrossRef
23.
go back to reference Lorenz MR, Holzapfel V, Musyanovych A, Nothelfer K, Walther P, Frank H, Landfester K, Schrezenmeier H, Mailander V (2006) Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials 27:2820–2828PubMedCrossRef Lorenz MR, Holzapfel V, Musyanovych A, Nothelfer K, Walther P, Frank H, Landfester K, Schrezenmeier H, Mailander V (2006) Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials 27:2820–2828PubMedCrossRef
24.
go back to reference Lewis GA, Mathieu D, Phan-Tan-Luu R (1999) Pharmaceutical experimental design. Dekker, New York Lewis GA, Mathieu D, Phan-Tan-Luu R (1999) Pharmaceutical experimental design. Dekker, New York
25.
go back to reference Hussain RF, Nouri AME, Oliver RTD (1993) A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160:89–96PubMedCrossRef Hussain RF, Nouri AME, Oliver RTD (1993) A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160:89–96PubMedCrossRef
26.
go back to reference Coradini D, Pellizzaro C, Scarlata I, Zorzet S, Garrovo C, Abolafio G, Speranza A, Fedeli M, Cantoni S, Sava G, Daidone MG, Perbellini A (2006) A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia 20:785–792PubMedCrossRef Coradini D, Pellizzaro C, Scarlata I, Zorzet S, Garrovo C, Abolafio G, Speranza A, Fedeli M, Cantoni S, Sava G, Daidone MG, Perbellini A (2006) A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia 20:785–792PubMedCrossRef
27.
go back to reference Drímalová E, Velebný V, Sasinková V, Hromádková Z, Ebringerová A (2005) Degradation of hyaluronan by ultrasonication in comparison to microwave and conventional heating. Carbohydr Polym 61:420–426CrossRef Drímalová E, Velebný V, Sasinková V, Hromádková Z, Ebringerová A (2005) Degradation of hyaluronan by ultrasonication in comparison to microwave and conventional heating. Carbohydr Polym 61:420–426CrossRef
28.
go back to reference Cowman MK, Matsuoka S (2005) Experimental approaches to hyaluronan structure. Carbohydr Res 340:791–809PubMedCrossRef Cowman MK, Matsuoka S (2005) Experimental approaches to hyaluronan structure. Carbohydr Res 340:791–809PubMedCrossRef
29.
go back to reference Hargittai I, Hargittai M (2008) Molecular structure of hyaluronan: an introduction. Struct Chem 19:697–717CrossRef Hargittai I, Hargittai M (2008) Molecular structure of hyaluronan: an introduction. Struct Chem 19:697–717CrossRef
30.
go back to reference Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Controll Release 70:399–421CrossRef Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Controll Release 70:399–421CrossRef
31.
go back to reference Verheul RJ, Amidi M, van Steenbergen MJ, van Riet E, Jiskoot W, Hennink WE (2009) Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. Biomaterials 30:3129–3135PubMedCrossRef Verheul RJ, Amidi M, van Steenbergen MJ, van Riet E, Jiskoot W, Hennink WE (2009) Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans. Biomaterials 30:3129–3135PubMedCrossRef
32.
go back to reference Furth G, Knierim R, Buss V, Mayer C (2008) Binding of bivalent cations by hyaluronate in aqueous solution. Int J Biol Macromol 42:33–40PubMedCrossRef Furth G, Knierim R, Buss V, Mayer C (2008) Binding of bivalent cations by hyaluronate in aqueous solution. Int J Biol Macromol 42:33–40PubMedCrossRef
33.
go back to reference Haxton KJ, Burt HM (2009) Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci 98:2299–2316PubMedCrossRef Haxton KJ, Burt HM (2009) Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci 98:2299–2316PubMedCrossRef
34.
go back to reference Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC (2008) Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Controll Release 127:41–49CrossRef Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC (2008) Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Controll Release 127:41–49CrossRef
35.
go back to reference Kruczynski A, Hill BT (2001) Classic in vivo cancer models: Three examples of mouse models used in experimental therapeutics. Curr Protoc Pharmacol Unit 5.24:5.24.1–5.24.16 Kruczynski A, Hill BT (2001) Classic in vivo cancer models: Three examples of mouse models used in experimental therapeutics. Curr Protoc Pharmacol Unit 5.24:5.24.1–5.24.16
36.
go back to reference Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaele D, Lepetre-Mouelhi S, Pili B, Bourgaux C, Amenitsch H, Ollivon M (2008) Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4:247–253PubMedCrossRef Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaele D, Lepetre-Mouelhi S, Pili B, Bourgaux C, Amenitsch H, Ollivon M (2008) Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4:247–253PubMedCrossRef
37.
go back to reference Nishioka Y, Yoshino H (2001) Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47:55–64PubMedCrossRef Nishioka Y, Yoshino H (2001) Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 47:55–64PubMedCrossRef
38.
go back to reference Bankhead C (2006) Intraperitoneal therapy for advanced ovarian cancer: will it become standard care? J Natl Cancer Inst 98:510–512PubMedCrossRef Bankhead C (2006) Intraperitoneal therapy for advanced ovarian cancer: will it become standard care? J Natl Cancer Inst 98:510–512PubMedCrossRef
39.
go back to reference Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J (2007) Hyaluronic acid-paclitaxel: antitumor efficacy against cd44(+) human ovarian carcinoma xenografts. Neoplasia 9:479–486PubMedCrossRef Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J (2007) Hyaluronic acid-paclitaxel: antitumor efficacy against cd44(+) human ovarian carcinoma xenografts. Neoplasia 9:479–486PubMedCrossRef
40.
go back to reference Lee H, Lee K, Park TG (2008) Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 19:1319–1325PubMedCrossRef Lee H, Lee K, Park TG (2008) Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 19:1319–1325PubMedCrossRef
41.
go back to reference Toole BP, Ghatak S, Misra S (2008) Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 9:249–252PubMedCrossRef Toole BP, Ghatak S, Misra S (2008) Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 9:249–252PubMedCrossRef
Metadata
Title
Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan
Authors
Sergio Cafaggi
Eleonora Russo
Rossana Stefani
Brunella Parodi
Gabriele Caviglioli
Greta Sillo
Angela Bisio
Cinzia Aiello
Maurizio Viale
Publication date
01-06-2011
Publisher
Springer US
Published in
Investigational New Drugs / Issue 3/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-009-9373-y

Other articles of this Issue 3/2011

Investigational New Drugs 3/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine